RESEARCH ARTICLE DOI: 10.53555/1vnsf209

PREVALENCE OF SUPERFICIAL FUNGAL INFECTION IN RENAL TRANSPLANTED PATIENTS

Manar Mohamed Abdelrahman Mohamed Ahmed^{1*}, Dr.Nahid Ahmed Basheer², Mohammed Abderahim Hassan³

Manar Mohamed Abdelrahman Mohamed Ahmed, Specialist Dermatologist, Primary Health Care Corporation, Doha, Qatar. Email: manarmohamed122224@gmail.com
²Dr.Nahid Ahmed Basheer, Consultant dermatologist, Khartoum teaching hospital.
³Mohammed Abderahim Hassan, Gastroenterologist, Hamad Medical Corporation. Email: Mhassan29@hamad.qa

*Corresponding Author: Manar Mohamed Abdelrahman Mohamed Ahmed, *Specialist Dermatologist, Primary Health Care Corporation, Doha, Qatar. Email: manarmohamed122224@gmail.com

Abstract

Background: Kidney transplantation is the treatment of choice for end-stage renal disease. However, patients require close follow-up after transplantation since they are on complex immunosuppressive regimens that render susceptible to infection, malignancy, and cardiovascular disease. Immunosuppressive dose also tends to be high in the first 1-6 months post transplantation and patients continue to be at risk of developing opportunistic fungal infection.

Aim: To determine prevalence and variant of superficial fungal infection in renal transplant recipient, to determine duration of immunosuppressive drugs used before appearance of superficial fungal infection and prevalence and to find out the relationship between types of immunosuppressive drugs used and prevalence of superficial fungal infection.

Methods: This cross-sectional descriptive hospital-based study was carried out on 80 patients with renal transplant recipients attended, admitted at hospital as well as referral clinics.

Results: Sixteen Patients (20%) had superficial fungal infections at the time of the study and 64 Patients (80.0%) had no superficial fungal infection. Regarding dermatological examination Skin involved in 13 Patients (16.2%), mucous membrane involved in 1 Patients (1.2%), nail Involved in 1 Patients (1.2%), Finger toe involved in 1 Patients (1.2%).

Conclusions: Pityriasis versicolor was the commonest superficial fungal infection in renal transplant recipients. Superficial fungal infection was more common in first 6months of treatment of immunosuppressive drugs and was more common in patient used combination of Azathioprine + predinsolone +prograf.

Keywords: Superficial Fungal Infection, Renal Transplanted Patients, Antibiotics, Cell Mediated Immunity

Introduction:

Fungi are eukaryotic organism whose cell walls are different from mammalian cell in that they contain ergosterol which is the target for the antifungal agent [1].

Fungal infections of the skin are also known as 'mycoses. They are common and generally mild. However, in very sick or otherwise immune suppressed people, fungi can sometimes cause serious disease [2].

Numerous ways of classifying superficial fungi exist, including habitat and pattern of infection. Geophilic organisms originate in the soil and only sporadically infect humans, usually by direct contact with the soil. These infections are usually spread by spores [3].

Zoophilic species are usually found on animals but are also transmitted to humans. (e.g., M. canis in cats and dogs) ^[4]. Inflammatory dermatophytoses are most produced by zoophilic dermatophytes. Anthropophilic species have adapted to humans as hosts ^[5].

Antibiotics are a risk factor for fungal infections ^[5]. Individuals with weakened immune systems are also at risk of developing fungal infections. This is the case of people with human immunodeficiency virus / acquired immunodeficiency syndrome, people under steroid treatments, and people taking chemotherapy. People with diabetes also tend to develop fungal infections ^[6].

Classification: Superficial fungal infections, subcutaneous fungal infections, systemic fungal in fections and opportunistic infection.

Superficial fungal infections, including dermatophytoses, candidacies, and pityriasis versicolor, are most often restricted to the epidermis ^[7].

Cutaneous Fungal infection also occur more frequently due to suppression of cell mediated immunity and possibly due to reduction of concentration of APC in the epidermis and can vary greatly in presentation [8].

Kidney transplantation is the treatment of choice for end-stage renal disease. However, patients require close follow-up after transplantation since they are on complex immunosuppressive regimens that render them susceptible to infection, malignancy, and cardiovascular disease ^[9].

Immunosuppressive dose also tend to be high in first 1- 6 months post transplantation and patient continue to be at risk of developing opportunistic fungal infection ^[10].

The aim of this work was to determine prevalence and variant of superficial fungal infection in renal transplant recipient, to determine duration of immunosuppressive drugs used before appearance of superficial fungal infection and prevalence and to find out the relationship between types of immunosuppressive drugs used and prevalence of superficial fungal infection.

Material and Method:

This cross-sectional descriptive hospital-based study was carried out on 80 patients of any age, both sexes, with renal transplant recipient attended, admitted at Ahmed Gasim hospital as well as referral clinics.

The study was done at Ahmed Gasim hospital for Cardiac Surgery and renal transplantation from May 2021 to May 2022 and was done in renal department which consist of a big theatre, room of recovery, ICU, center files of renal dialysis, outpatient clinics and tow refer clinics every week. The Ethics Review Committee of Sudan Medical Specialization board council of dermatology and venerology for approval of the study. After approval permission to conduct the survey was taken from the authorities of health care in the study area. I tried in gentle and respectful ways to assure all patients that all their obtained information will be treated in a confidential atmosphere, and it will not affect their life after taking verbal or written consent.

Exclusion criteria were patients refused to participate in the study and their autoimmune disease.

Data will be collected using specifically designed questionnaires which will include history, examination and investigation (nail clipping, skin scrapping).

The research team will include patients, researchers, dermatologists and statisticians.

Statistical analysis

Statistical analysis was performed using statistical package for social science (SPSS). A descriptive analysis was done for all questionnaire parameters.

Results:

Thirty-one (38.7%) of patients were from Khartoum state patients while14 patients (17.5%) from Aljazeera state, the rest of patients from other states. Table 2 showed the duration of renal transplantation, less than 6-month duration were 18 patients (22.5%), 6 month - 2 years 8 patients (22.5%), 2 - 4 years 15 patients (18.8%), 4-6 years 12 patients (15.0%), 8-- 10 year5 patients (6.2%), More than 10 years 4 patients (5.0%). Immunosuppressive Drugs used In Renal Transplant Patients as follow.

Table 1

Azathioprine + 1052rednisolone +prograf "tacrolimus51 Patients (63.7 %), Cyclosporine + 1052rednisolone + cellcept (mycophenolate) 9 Patients (11.2 %), Azithropine + Cyclosporine+ predinsolon 6 Patients (7.5 %), 1052rednisolone + prograf + cellcept (mycophenolate) 14 Patients (17.4 %). **Table 1**

Table 1: Resident s of renal transplant patients in Ahmed Gasim hospital time between May2021 _ May 2022, duration since renal transplantation and immunosuppressive drugs used in renal transplant patients

used in Tenat Gansplant patients					
State					
Khartoum State	31 (38.7%)				
Darfoor	1 (1.2%)				
Kordofan	5 (6.2%)				
North State	5 (6.2%)				
White Nile State	7 (8.8%)				
Aljazeera	14 (17.5%)				
Blue Nile State	3 (3.8%)				
Red Sea State	3 (3.8%)				
River Nile State	7 (8.8%)				
Kassala	4 (5.0%)				
Total	80 (100%)				
Duration Since Renal Transplantation					
Less than 6 months	18 (22.5%)				
6 months - 2 Years	18 (22.5%)				
2 - 4 years	15 (18.8%)				
4 - 6 years	12 (15%)				
6 - 8 years	8 (10%)				
8 - 10 Years	5 (6.2%)				
More than 10 Years	4 (5.0%)				
Total	80 (100%)				
Immunosuppressive Drugs					
Azathioprine + Prednisolone + Prograf (Tacrolimus)	51 (63.7%)				
Cyclosporine + Prednisolone + Cellcept	9 (11.2%)				
Azathioprine + Cyclosporine + Prednisolone	6 (7.5%)				
Prednisolone + Prograf + Cellcept	14 (17.4%)				
Total	80 (100.0%)				

Data was presented as frequency %.

Regarding dermatological examination Skin involved in 13 Patients (16.2%), mucous membrane involved in1 Patients (1.2%), nail Involved in1 Patient (1.2%), Finger toe involved in1 Patients (1.2%). Skin scraping done for 12. Patients and was positive Nail clipping done for 3 Patients and was positive in1 Patient. **Table 2**

Table 2: Dermatological examination in renal transplant patients in Ahmed Gasim hospital time between May 2021 - May 2022

time setween iving 2021 iving 2022				
Site	Yes (Count, %)	No (Count, %)		
Skin	13 (16.2%)	67 (83.8%)		
Mucous membrane	1 (1.2%)	79 (98.8%)		
Nail	1 (1.2%)	79 (98.8%)		
Scalp	0 (0%)	80 (100%)		
Finger toe	1 (1.2%)	79 (98.8%)		

Data was presented as frequency %.

Skin scraping done for 12 patients and was positive Nail clipping done for three patients and was positive in one patient. **Table 3**

Table 3: Investigation in renal transplant patients in Ahmed Gasim hospital May 2021 _ May 2022

Sample Type	Total (Count)	Positive (Count)	Negative (Count)
Skin scraping	12	12	0
Nail clipping	1	1	0

Superficial fungal infection more common in first 6month of treatment of immunosuppressive drug 5 Patients (31.20 %),6 month - 2 years2 Patients (12.50 %), 2 - 4 years2 Patients (12.50 %), 4- 6 years 4 Patients (25 %),6- 8 years1 Patient (6.20 %), more than 10 years (12.50) 2 Patients. **Table 4**

Table 4: Relationship between Duration Immunosuppressive drugs &prevalence of superficial fungal infection in renal transplant patients

tungai infection in renai transpiant patients							
Variant of Superficial Fungal Infection	Less than 6 months	6 months - 2 years	2 - 4 years	4 - 6 years	6 - 8 years	More than 10 years	Total
Spityriasis Versicolor	3 (18.8%)	1 (6.2%)	2 (12.5%)	4 (25.0%)	0 (0.0%)	1 (6.2%)	11(68.8%)
Tinea Pedis	0 (0.0%)	1 (6.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (6.2%)
Onychomycosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1(6.2%)	1 (6.2%)
Tinea Cruris	1 (6.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (6.2%)
Oral Candidiasis	1 (6.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (6.2%)
Tinea Corporis	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (6.2%)	0 (0.0%)	1 (6.2%)
Total	5 (31.2%)	2(12.5%)	2 (12.5%)	4 (25.0%)	1 (6.2%)	(12.5%)	16 (100%)

Data was presented as frequency%

Superficial fungal infection was more common in patients used combination of Azathioprine + predinsolone + prograf 9 Patients (56.20 %), while those who were using of Cyclosporine + predinsolone + cellcept 4Patients is (25 %), Azathioprine + Cyclosporine+ predinsolon 2Patients (12.5 %), and predinsolone + prograf + cellcept1 patient (6.20 %). **Table 5**

Table 5: Relationship between duration immunosuppressive drugs &prevalence of superficial fungal infection in renal transplant patients

Superficial	Azathioprine	Cyclosporine	Azathioprine	Prednisolone	Total
Fungal	+	+	+	+ Prograf +	
Infection			Cyclosporine	Cellcept	

	Prednisolone	Prednisolone	+		
	+ Prograf	+ Cellcept	Prednisolone		
Pityriasis	6 (37.5%)	3 (18.8%)	1 (6.2%)	1 (6.2%)	11(68.8%)
Versicolor					
Tinea Pedis	0 (0.0%)	1 (6.2%)	0 (0.0%)	0 (0.0%)	1 (6.2%)
Onychomycosis	0 (0.0%)	0 (0.0%)	1 (6.2%)	0 (0.0%)	1 (6.2%)
Tinea Cruris	1 (6.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (6.2%)
Oral	1 (6.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (6.2%)
Candidiasis					
Tinea Corporis	1 (6.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (6.2%)
Total	9 (56.2%)	4 (25.0%)	2 (12.5%)	1 (6.2%)	16 (100%)

Data was presented as frequency %

Discussion

The key finding from this study is that 16 Patient (20.0 %), of our patients with renal transplant recipients had superficial fungal infection and 64 (80.0 %), of them had no superficial fungal infection, this similar result in the study of virgili A et al. [11] and disagree with study of Güleç AT¹ et al [3] and stuy of Imko-Walczuk et al. [12] and this explain by small sample in contrast by those studies.

Pityriasis versicolor was the commonest superficial fungal infection in renal transplant recipients found in 11 Patients (68.8%), This is agree with results from study conducted in northern Italy by virgiliA et al. [11] and also agree with study of Güleç AT¹ et al. [11], and diss agree with study of Imko-Walczuk et al. [11] which found oral candidiasis was the commonest

Superficial fungal infection more common in first six months of treatment of immunosuppressive drugs this result agree with result from study conducted in Poland byImko-Walczuk et al. $^{[12]}$ and agree with result form study of Güleç AT^{1} and this explain by immunosuppressive dose also tend to be high in first 1-6 months post transplantation

superficial fungal infection was more common in patient used combination of Azathioprine + predinsolone + prograf this diss agree with results from study of virgiliA et al [11] which found The prevalence of superficial fungal infection was higher in the group of patients treated with Azathioprine -cyclosporine-steroids and this explain by that most of our patients used combination of Azathioprine + predinsolone + prograf 51patients (63.7%).

Recommendations: Dermatological clinic should be performed in renal transplant centre

Patient should be aware of the clinical course of fungal species in RTRs compared with the general population. Education of the patients how to care for their skin.

Further studies should be performed with focus in larger population in other renal transplant centre to find the most suitable regiment of treatment that give proper immunosuppression with less side effect.

Conclusions:

Pityriasis versicolor was the commonest superficial fungal infection in renal transplant recipients. Superficial fungal infection was more common in first 6months of treatment of immunosuppressive drugs and was more common in patient used combination of Azathioprine + predinsolone +prograf.

Financial support and sponsorship: Nil

Conflict of Interest: Nil

References:

- 1. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12:501-17.
- 2. Howell SA. Dermatopathology and the diagnosis of fungal infections. Br J Biomed Sci. 2023;80:11314.

- 3. Björnsdóttir S, Gottfredsson M, Thórisdóttir AS, Gunnarsson GB, Ríkardsdóttir H, Kristjánsson M, et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis. 2005;41:1416-22.
- 4. Bryant AE, Bayer CR, Chen RY, Guth PH, Wallace RJ, Stevens DL. Vascular dysfunction and ischemic destruction of tissue in streptococcus pyogenes infection: The role of streptolysin o-induced platelet/neutrophil complexes. J Infect Dis. 2005;192:1014-22.
- 5. Bradley SF. Staphylococcus aureus infections and antibiotic resistance in older adults. Clin Infect Dis. 2002;34:211-6.
- 6. Manders SM. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol. 1998;39:383-98; quiz 99-400.
- 7. Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol. 1997;36:788-92.
- 8. Sardana K, Gupta A, Mathachan SR. Immunopathogenesis of dermatophytoses and factors leading to recalcitrant infections. Indian Dermatol Online J. 2021;12:389-99.
- 9. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med. 1994;331:365-76.
- 10. Lally A, Casabonne D, Imko-Walczuk B, Newton R, Wojnarowska F. Prevalence of benign cutaneous disease among Oxford renal transplant recipients. J Eur Acad Dermatol Venereol. 2011;25:462-70.
- 11. Güleç AT, Demirbilek M, Seçkin D, Can F, Saray Y, Sarifakioglu E, et al. Superficial fungal infections in 102 renal transplant recipients: a case-control study. J Am Acad Dermatol. 2003;49:187-92.
- 12. Imko-Walczuk B, Prędota A, Okuniewska A, Jaśkiewicz J, Zegarska B, Placek W, et al., editors. Superficial fungal infections in renal transplant recipients. Transplantation Proceedings; 2014: Elsevier.